Risk Factors for Predicting Osteoporosis in Patients Who Receive Thyrotropin Suppressive Levothyroxine Treatment for Differentiated Thyroid Carcinoma

SOYDAL Ç., ÖZKAN E., Nak D., ELHAN A. H., KÜÇÜK N. Ö., KIR K. M.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.28, no.2, pp.69-75, 2019 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.4274/mirt.galenos.2019.89410
  • Journal Name: MOLECULAR IMAGING AND RADIONUCLIDE THERAPY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.69-75
  • Keywords: Differentiated thyroid carcinoma, osteoporosis, thyroid-stimulating hormone suppression treatment, BONE-MINERAL DENSITY, HORMONE SUPPRESSION, CANCER, THERAPY, MANAGEMENT, FRACTURE, OUTCOMES
  • Ankara University Affiliated: Yes

Abstract

Objectives: Endogenous hyperthyroidism accelerates bone turnover and shortens the normal bone remodeling cycle, which results in reduced bone density. It is estimated that suppressive levothyroxine (LT4) therapy also decreases bone density. The aim of this study was to define risk factors for osteoporosis development in patients under thyrotropin-stimulating hormone (TSH) suppressive treatment for differentiated thyroid cancer (DTC).